Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Equity (2016 - 2025)

Historic Return on Equity for Celldex Therapeutics (CLDX) over the last 15 years, with Q3 2025 value amounting to 0.36%.

  • Celldex Therapeutics' Return on Equity fell 1700.0% to 0.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.36%, marking a year-over-year decrease of 1700.0%. This contributed to the annual value of 0.27% for FY2024, which is 1100.0% up from last year.
  • Per Celldex Therapeutics' latest filing, its Return on Equity stood at 0.36% for Q3 2025, which was down 1700.0% from 0.29% recorded in Q2 2025.
  • Celldex Therapeutics' 5-year Return on Equity high stood at 0.16% for Q4 2021, and its period low was 0.48% during Q3 2023.
  • Over the past 5 years, Celldex Therapeutics' median Return on Equity value was 0.29% (recorded in 2025), while the average stood at 0.29%.
  • As far as peak fluctuations go, Celldex Therapeutics' Return on Equity plummeted by -1900bps in 2023, and later soared by 2800bps in 2024.
  • Celldex Therapeutics' Return on Equity (Quarter) stood at 0.16% in 2021, then tumbled by -103bps to 0.33% in 2022, then fell by -25bps to 0.42% in 2023, then surged by 51bps to 0.21% in 2024, then tumbled by -74bps to 0.36% in 2025.
  • Its Return on Equity stands at 0.36% for Q3 2025, versus 0.29% for Q2 2025 and 0.25% for Q1 2025.